



Atty. Dkt. No. 029996-0306374
Pat. App. Ser. No. 10/697,700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Pownall, et al.

Group Art Unit: to be assigned

Appln. No.: 10/697,700

Examiner: to be assigned

Filed: October 29, 2003

Title: CANCER TREATMENTS BY METABOLIC MODULATIONS

TRANSMITTAL LETTER

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing Under 37 C.F.R. §1.8
I hereby certify that this correspondence along with any paper referred to as being attached is being Mailed to Addressee by service of the United States Postal Service addressed to Commissioner for Patents, P.O. Box, 1450, Alexandria, VA 22313-1450

Date: February 24, 2004

By: 
Sachiko Y. Snedden

Sir:

Transmitted herewith for filing are the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. Cited References (137); and
4. Return Postcard.

No fee is believed to be incurred for filing this Inquiry. However, the Commissioner is hereby authorized to charge any fee that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account 50-2212. A duplicate of this Transmittal is enclosed.


Respectfully submitted,

Pillsbury Winthrop LLP

Date: February 24, 2004

11682 El Camino Real, Suite 200
San Diego, CA 92130-2092
(619) 234-5000

By:


Robert M. Bedgood, Ph.D.
Reg. No. 43,488
Tel. No. (858) 509-4065
Fax No. (858) 509-4010



Atty Dkt No. 029996-0306374
Pat. App. Ser. No. 10/697,700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Pownall, et al.

Group Art Unit: to be assigned

Appln. No.: 10/697,700

Examiner: to be assigned

Filed: October 29, 2003

Title:
CANCER TREATMENTS BY METABOLIC
MODULATIONS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is Form PTO-1449 listing the enclosed cited references in this statement.

Contingent Request Under Rule 97(c): Should a first action on the merits have been issued on the same day or before this Information Disclosure Statement is filed, please accept this Information Disclosure Statement under Rule 97(c) and charge the requisite Rule 17(p) fee to our Deposit Account No. 50-2212, under the above Atty Dkt. No., and proceed to consider this Information Disclosure Statement.

Certificate of Mailing Under 37 C.F.R. §1.8

I hereby certify that this correspondence along with any paper referred to as being attached is being Mailed to Addressee by service of the United States Postal Service addressed to Commissioner for Patents, P.O. Box, 1450, Alexandria, VA 22313-1450

By: 
Sachiko Y. Snedden

Date: February 24, 2004

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.


This Information Disclosure Statement is not to be constructed as a representation that any of the listed citations establishes, by itself or in combination with other information, a prima facie case of unpatentability of any claim in the above-identified patent application. Additionally, this Information Disclosure Statement is not to be constructed as a representation that a further search of the art has been made by the Applicant, or that additional information unknown to the Applicant and relevant to the examination of this patent application does not exist.

Consideration of the foregoing and enclosures plus the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited along with an early action on the merits.

Respectfully submitted,

Pillsbury Winthrop LLP

By



Robert M. Bedgood, Ph.D.
Reg. No. 43,488

Date: February 24, 2004

Tel. No. (858) 509-4065

Fax No. (858) 509-4010

11682 El Camino Real
Suite 200
San Diego, CA 92130-2092
(619) 234-5000



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

029996-0306374

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: Pownall, et al.

Appln. No.: 10/697,700

Filing Date: October 29, 2003

Date: February 13, 2004

Page

1

of

13

Examiner: to be assigned

Art Unit: to be assigned

U.S. PATENT DOCUMENTS

| Examiner's Initials* | Document Number | Date MM/YYYY | Name (Family Name of First Inventor) | Class | Sub Class | Filing Date (if appropriate) |
|-------------------------|--------------------|-----------------|---|--------------|--------------|---------------------------------|
| | AR | 2002/0123513 A1 | 09/2002 | Krasner | | |
| | BR | 2003/0166592 A1 | 09/2003 | Monia et al. | | |
| | CR | 6,297,359 B1 | 10/2001 | Young et al. | | |
| | DR | | | | | |
| | ER | | | | | |
| | FR | | | | | |
| | GR | | | | | |
| | HR | | | | | |
| | IR | | | | | |
| | JR | | | | | |
| | KR | | | | | |
| | LR | | | | | |
| | MR | | | | | |
| | NR | | | | | |


FOREIGN PATENT DOCUMENTS

| Examiner's Initials* | Document Number | Date MM/YYYY | Country | Inventor Name | English Abstract | | Translation Readily Available | |
|-------------------------|--------------------|-----------------|---------|---------------|---------------------|----|-------------------------------------|----|
| | | | | | Enclosed | No | Enclosed | No |
| | OR | | | | | | | |
| | PR | | | | | | | |
| | QR | | | | | | | |
| | RR | | | | | | | |
| | SR | | | | | | | |
| | TR | | | | | | | |
| | UR | | | | | | | |
| | VR | | | | | | | |
| | WR | | | | | | | |
| | XR | | | | | | | |

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

029996-0306374

Applicant: Pownall, et al.

Appln. No.: 10/697,700

Filing Date: October 29, 2003

Examiner: to be assigned

Art Unit: to be assigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: February 13, 2004

Page

2

of

13


OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

| Examiner's Initials* | | | English Abstract | | Translation Readily Available | |
|-------------------------|-----|--|---------------------|----|-------------------------------------|----|
| | | | Enclosed | No | Enclosed | No |
| | YR | Bernard-Hélary et al.; Stable Transfection of cDNAs Targeting Specific Steps of Glycogen Metabolism Supports the Existence of Active Gluconeogenesis in Mouse Cultured Astrocytes; GLIA 37; 2002; p. 379-382 | | | | |
| | ZR | Somsak et al.; Glucose Analog Inhibitors of Glycogen Phosphorylases as Potential Antidiabetic Agents: Recent Developments; Current Pharmaceutical Design Vol. 9, No. 15; 2003; p. 1177-1189 | | | | |
| | AAR | Yu et al.; Simultaneous Inhibition of GSK3 α and GSK3 β Using Hairpin siRNA Expression Vectors; Molecular Therapy Vol. 7, No. 2; 02/2003; p. 228-236 | | | | |
| | ABR | Legler; Glycoside Hydrolases: Mechanistic Information from Studies with Reversible and Irreversible Inhibitors; Advances in Carbohydrate Chemistry and Biochemistry Vol. 48; 1990; p. 319-384 | | | | |
| | ACR | Stambolic et al.; Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells; Current Biology Vol. 6, No. 12; 1996; p. 1664-1668 | | | | |
| | ADR | Robinson et al.; New Potent α -Glucohydrolase Inhibitor MDL 73945 With Long Duration of Action in Rats; Diabetes Vol. 40; 06/1991; p. 825-830 | | | | |
| | AER | Wisselaar et al.; Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral- and asid α -glucosidases in Human Fibroblasts and HepG2 Cells; Clinica Chimica Acta 182; 1989; p. 41-52 | | | | |
| | AFR | Yamanouchi et al.; Metabolic Effects of Proglycosyn; Archives of Biochemistry and Biophysics Vol. 294, No. 2; 05/1992; p. 609-615 | | | | |
| | AGR | Bischoff; Pharmacology of α -glucosidase inhibition; European Journal of Clinical Investigation 24, Suppl. 3; 1994; p. 3-10 | | | | |
| | AHR | Lebovitz; Oral Antidiabetic Agents, The Emergence of α -Glucosidase Inhibitors; Drugs 44, Suppl. 3; 1992; p. 21-28 | | | | |
| | AIR | Al-Habori et al.; The role of cell swelling in the stimulation of glycogen synthesis by insulin; Biochem. J. 282; 1992; p. 789-796 | | | | |
| | AJR | Allaman et al.; Protein Targeting to Glycogen mRNA Expression Is Stimulated by Noradrenaline in Mouse Cortical Astrocytes; GLIA 30; 2000; p. 382-391 | | | | |
| | AKR | Alemzadeh et al.; Chronic suppression of insulin by diazoxide alters the activities of key enzymes regulating hepatic gluconeogenesis in Zucker rats; European Journal of Endocrinology 146; 2002; p. 871-879 | ✓ | | | |

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

029996-0306374

Applicant: Pownall, et al.

Appln. No.: 10/697,700

Filing Date: October 29, 2003

Examiner: to be assigned

Art Unit: to be assigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: February 13, 2004

Page

3

of

13

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner's

Initials*

English
Abstract

Translation
Readily
Available

Enclosed

No

Enclosed

No

ALR

Arai et al.; N-Methyl-1-Deoxynojirimycin (MOR-14), an α -Glucosidase Inhibitor, Markedly Reduced Infarct Size in Rabbit Hearts; Circulation; 04/1998; p. 1290-1297

AMR

Chishti et al.; Ultrastructural Alterations Produced in Cockerels after Mercuric Chloride Toxicity and Subsequent Interaction with an Organophosphate Insecticide; Archives of Environmental Contamination and Toxicology 22; 1992; p. 445-451

ANR

Baek et al.; Acarviosine-simmondsin, a Novel Compound Obtained from Acarviosine-glucose and Simmondsin by *Thermus* Maltogenic Amylase and Its *in vivo* Effect on Food Intake and Hyperglycemia; Biosci. Biotechnol. Biochem., 37 (3); 2003; p. 532-539

AOR

Balbua et al.; Inhibition of some hepatic lysosomal glycosidases by ethanolamines and phenyl 6-deoxy-6-(morpholin-4-yl)- β -D-glucopyranoside; Carbohydrate Research 317; 1999; p.100-109

APR

Bax et al; The Structure of Phosphorylated GSK-3 β Complexed with a Peptide, FRATide, that Inhibits β -Catenin Phosphorylation; Structure Vol. 9; 12/2001; p. 1143-1152

AQR

Beckerbauer et al.; FR900482 class of anti-tumor drugs cross-links oncoprotein HMG I/Y to DNA *in vivo*; Chemistry & Biology Vol. 7, No. 10; 2000; p. 805-812

ARR

Bergans et al.; Molecular Mode of Inhibition of Glycogenolysis in Rat Liver by the Dihydropyridine Derivative, BAY R3401; Diabetes Vol. 49; 09/2000; p.1419-1426

ASR

Berger et al.; A High-Capacity Assay for Activators of Glucose Incorporation into Glycogen in L6 Muscle Cells; Analytical Biochemistry 261; 1998; p. 159-163

ATR

Black; Influence of hormones on glycogen and glucose metabolism in embryonic chick intestine; Am. J. Physiol. 254 (Gastrointest. Liver Physiol. 17); 1988; p. G65-G73

AUR


Board; N-Acetyl- β -D-glucopyranosylamine 6-phosphate is a specific inhibitor of glycogen-bound protein phosphatase 1; Biochem. J. 328; 1997; p. 695-700

✓

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

029996-0306374

Applicant: Pownall, et al.

Appln. No.: 10/697,700

Filing Date: October 29, 2003

Examiner: to be assigned

Art Unit: to be assigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: February 13, 2004

Page

4

of

13


OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

| Examiner's Initials* | | | English Abstract | | Translation Readily Available | |
|-------------------------|-----|--|---------------------|----|-------------------------------------|----|
| | | | Enclosed | No | Enclosed | No |
| | AVR | Bosch et al.; Epidermal growth factor mimics insulin effects in rat hepatocytes; Biochem. J. 239; 1986; p. 523-530 | | | | |
| | AWR | Braun et al.; Mechanism-based Inhibition of Yeast α -Glucosidase and Human Pancreatic α -Amylase by a New Class of Inhibitors; The Journal of Biological Chemistry Vol. 270, No. 45; 11/1995; p. 26778-26781 | | | | |
| | AXR | Breton et al.; The Natural Product Hymenialdisine Inhibits Interleukin-8 Production in U937 Cells by Inhibition of Nuclear Factor- κ B; The Journal of Pharmacology and Experimental Therapeutics Vol. 282, No. 1; 1997; p. 459-466 | | | | |
| | AYR | Carmichael et al.; Glycogen Synthase Kinase-3 β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington's Disease Mutation; The Journal of Biological Chemistry Vol. 277, No. 37; 09/2002; p. 33791-33798 | | | | |
| | AZR | Chambers et al.; Nojirimycin-A Potent Inhibitor of Purified Lysosomal Alpha-Glucosidase from Human Liver; Biochemical and Biophysical Research Communications Vol. 107, No. 4; 08/1982; p. 1490-1496 | | | | |
| | BAR | Cross et al.; Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B; Nature Vol. 378; 12/1995; p. 785-789 | | | | |
| | BBR | Cross et al.; Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death; Journal of Neurochemistry 77; 2001; p. 94-102 | | | | |
| | BCR | Cull et al.; Screening for receptor ligands using large libraries of peptides linked to the C terminus of the <i>lac</i> repressor; Proc. Natl. Acad. Sci. USA Vol. 89, Biochemistry; 03/1992; p. 1865-1869 | | | | |
| | BDR | Cwirla et al.; Peptides on phage: A vast library of peptides for identifying ligands; Proc. Natl. Acad. Sci. USA Vol. 87, Biochemistry; 08/1990; p. 6378-6382 | | | | |
| | BER | Dajani et al.; Crystal Structure of Glycogen Synthase Kinase 3 β : Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition; Cell Vol. 105; 06/2001; p. 721-732 | | | | |
| | BFR | Damiens et al.; Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest; Oncogene 20; 2001; p. 3786-3797 | ✓ | | | |

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

| | | |
|-------------------|----------------|-------------|
| Atty. Dkt. No. | M# | Client Ref. |
| | 029996-0306374 | |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| |
|--|
| Applicant: Pownall, et al. |
| Appln. No.: 10/697,700 |
| Filing Date: October 29, 2003 |
| Examiner: to be assigned Art Unit: to be assigned |

Date: February 13, 2004 Page 5 of 13

| OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) | | | English Abstract | | Translation Readily Available | |
|---|-----|--|---------------------|----|-------------------------------------|----|
| Examiner's Initials* | | | Enclosed | No | Enclosed | No |
| | BGR | Detaille et al.; Cellular and Molecular Mechanisms Involved in Insulin's Potentiation of Glycogen Synthase Activity by Metformin; Biochemical Pharmacology Vol. 58; 1999; p. 1475-1486 | | | | |
| | BHR | Dwivedi et al.; Pathology of ochratoxicosis A in young broiler chicks; Research in Veterinary Science 36; 1984; p. 92-103 | | | | |
| | BIR | DeWitt et al.; "Diversomers": An approach to nonpeptide, nonoligomeric chemical diversity; Proc. Natl. Acad. Sci. USA Vol. 90, Chemistry; 08/1993; p. 6909-6913 | | | | |
| | BJR | Donello et al.; Woodchuck Hepatitis Virus Contains a Tripartite Posttranscriptional Regulatory Element; Journal of Virology Vol. 72, No. 6; 06/1998; p. 5085-5092 | | | | |
| | BKR | Dong et al.; Evaluation of Isofagomine and Its Derivatives As Potent Glycosidase Inhibitors; Biochemistry 35; 1996; p. 2788-2795 | | | | |
| | BLR | Elbein; Inhibitors of the Biosynthesis and Processing of N-linked Oligosaccharide Chains; Ann. Rev. Biochem. 56; 1987; p. 497-534 | | | | |
| | BMR | Erb et al.; Recursive deconvolution of combinatorial chemical libraries; Proc. Natl. Acad. Sci. USA Vol. 91, Chemistry; 11/1994; p. 11422-11426 | | | | |
| | BNR | Felici et al.; Selection of Antibody Ligands from a Large Library of Oligopeptides Expressed on a Multivalent Exposition Vector; J. Mol. Biol. 222; 1991; p. 301-310 | | | | |
| | BOR | Field et al.; Histidines, Histamines and imidazoles as glycosidase inhibitors; Biochem. J. 274; 1991; p. 885-889 | | | | |
| | BPR | Fiol et al.; Formation of Protein Kinase Recognition Sites by Covalent Modification of the Substrate; The Journal of Biological Chemistry Vol. 262, No. 29; 10/1987; p. 14042-14048 | | | | |
| | BQR | Fiol et al.; Phosphoserine as a Recognition Determinant for Glycogen Synthase Kinase-3: Phosphorylation of a Synthetic Peptide Based on the G-Component of Protein Phosphatase-1; Archives of Biochemistry and Biophysics Vol. 267, No. 2; 12/1988; p. 797-802 | | | | |
| | BRR | Fiol et al.; Ordered Multisite Protein Phosphorylation, Analysis of Glycogen Synthase Kinase 3 Action Using Model Peptide Substrates; The Journal of Biological Chemistry Vol. 265, No. 11; 04/1990; p. 6061-6065 | ✓ | | | |

Examiner _____ Date Considered: _____

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

| | | |
|-------------------|----------------|-------------|
| Atty. Dkt. No. | M# | Client Ref. |
| | 029996-0306374 | |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| |
|--|
| Applicant: Pownall, et al. |
| Appln. No.: 10/697,700 |
| Filing Date: October 29, 2003 |
| Examiner: to be assigned Art Unit: to be assigned |

Date: February 13, 2004 Page 6 of 13

| OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.) | | | English Abstract | | Translation Readily Available | |
|--|-----|---|------------------|----|-------------------------------|----|
| Examiner's Initials* | | | Enclosed | No | Enclosed | No |
| | BSR | Firsov; Comparative Study of Mechanism of Action of Glucosidase from Bovine Liver and Exogluconase from <i>Aspergillus awamori</i> ; 1979; p. 1757-1766 | | | | |
| | BTR | Flamm et al.; Inulin and Oligofructose as Dietary Fiber: A Review of the Evidence; Critical Reviews in Food Science and Nutrition, 41(5); 2001; p. 353-362 | | | | |
| | BUR | Fl  oyen et al.; Glycogen Accumulation and Histological Changes in the Livers of Lambs with Alveld and Experimental Sporidesmin Intoxication; Veterinary Research Communications, 15; 1991; p. 443-453 | | | | |
| | BVR | Fl  ckiger-Isler et al.; Stimulation of rat liver glycogen synthesis by the adenosine kinase inhibitor 5-iodotubercidin; Biochem J. 292; 1993; p. 85-91 | | | | |
| | BWR | Fodor et al.; Multiplexed biochemical assays with biological chips; Nature Vol. 364; 08/1993; p. 555-556 | | | | |
| | BXR | Forlenza et al.; Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3   inhibition and in neurons; Journal of Neural Transmission 107; 2000; p. 1201-1212 | | | | |
| | BYR | Fosgerau et al.; Kinetic and Functional Characterization of 1,4-Dideoxy-1,4-imino-D-arabinitol: A Potent Inhibitor of Glycogen Phosphorylase with Anti-hyperglycemic Effect in ob/ob Mice; Archives of Biochemistry and Biophysics Vol. 380, No. 2; 08/2000; p. 274-284 | | | | |
| | BZR | Gallop et al.; Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries; Journal of Medical Chemistry Vol. 37, No. 9; 04/1994; p. 1233-1251 | | | | |
| | CAR | Gergely et al.; Effect of fructose 1-phosphate on the activation of liver glycogen synthase; Biochem. J. 232, 1985; p. 133-137 | | | | |
| | CBR | G  ke et al.; Voglibose (AO-128) Is an Efficient   -Glucosidase Inhibitor and Mobilizes the Endogenous GLP-1 Reserve; Digestion 56; 1995; p. 493-501 | | | | |
| | CCR | Halvorson et al.; The Purification and Properties of an   -Glucosidase of <i>Saccharomyces Italicus</i> Y1225; Biochimica et Biophysica Acta Vol. 30; 1958; p. 28-40 | | | | |
| | CDR | Hermans et al.; Human Lysosomal   -Glucosidase; The Journal of Biological Chemistry Vol. 266, No. 21, 07/1991; p. 13507-13512 |    | | | |

| | |
|---|------------------|
| Examiner | Date Considered: |
| *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP    609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | |



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

029996-0306374

Applicant: Pownall, et al.

Appln. No.: 10/697,700

Filing Date: October 29, 2003

Examiner: to be assigned

Art Unit: to be assigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: February 13, 2004

Page

7

of

13

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)


| Examiner's Initials* | | | English Abstract | | Translation Readily Available | |
|-------------------------|-----|--|---------------------|----|-------------------------------------|----|
| | | | Enclosed | No | Enclosed | No |
| | CER | Hers et al.; The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity; FEBS Letters 460; 1999; p. 433-436 | | | | |
| | CFR | Hevor et al.; Biochemical and Ultrastructural Study of Glycogen in Cultured Astorocytes Submitted to the Convulsant Methionine Sulfoximine; GLIA 4; 1991; p. 64-69 | | | | |
| | CGR | Fujita et al; Efficacy and safety of Touch Extract, an α -glucosidase inhibitor derived from fermented soybeans, in non-insulin-dependent diabetic mellitus; The Journal of Nutritional Biochemistry 12; 2001; p. 351-356 | | | | |
| | CHR | Hoover et al.; Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase; Journal of Medical Chemistry Vol. 41, No. 16; 1998; p. 2934-2938 | | | | |
| | CIR | Ikeda et al.; Homonojirimycin analogues and their glucosides from <i>Lobelia sessilifolia</i> and <i>Adenophora</i> spp. (Campanulaceae); Carbohydrate Research 323; 2000; p.73-80 | | | | |
| | CJR | Houghten et al.; The Use of Syntnetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides; BioTechniques Vol. 13, No. 3; 1992; p. 412-421 | | | | |
| | CKR | Ilouz et al.; Inhibition of glycogen synthase kinase-3 β by bivalent zinc ions: insight into the insulin-mimetic action of zinc; Biochemical and Biophysical Research Communications 295; 2002; p. 102-106 | | | | |
| | CLR | Itinose et al; N-Acetylcysteine Stimulates Hepatic Glycogen Deposition in the Rat; Research Commucations in Chemical Pthology and Pharmacology Vol. 83, No. 1; 01/1994; p. 87-92 | | | | |
| | CMR | Kaiser et al.; The Cyclin-Dependent Kinase (CDK) Inhibitor Flavopiridol Inhibits Glycogen Phosphorylase; Archives of Biochemistry and Biophysics Vol. 386, No. 2; 02/2001; p. 179-187 | | | | |
| | CNR | Kato-Weinstein et al; Effects of dichloroacetate on glycogen metabolism in B6C3F1 mice; Toxicology 130; 1998; p. 141-154 | | | | |
| | COR | Kay et al.; Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector; Nature Genetics Vol. 24; 03/2000; p. 257-261 | ✓ | | | |

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty.
Dkt. No.

M#

Client Ref.

029996-0306374

Applicant: Pownall, et al.

Appln. No.: 10/697,700

Filing Date: October 29, 2003

Examiner: to be assigned

Art Unit: to be assigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: February 13, 2004

Page

8

of

13

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner's

Initials*

English

Abstract

Translation

Readily
Available

Enclosed No


Enclosed No

| | | | | | |
|-----|---|---|--|--|--|
| CPR | Kennerdell et al.; Use of dsRNA-Mediated Genetic Interference to Demonstrate that <i>frizzled</i> and <i>frizzled 2</i> Act in the Wingless Pathway; Cell Vol. 95; 12/1998; p. 1017-1026 | | | | |
| CQR | Kim et al.; Comparative Study of the Inhibition of α -Glucosidase, α -Amylase, and Cyclomaltodextrin Glucanotransferase by Acarbose, Isoacarbose, and Acarviosine-Glucose; Archives of Biochemistry and Biophysics Vol. 371, No. 2; 11/1999; p. 277-283 | | | | |
| CRR | Klein et al.; A molecular mechanism for the effect of lithium on development; Proc. Natl. Acad. Sci. USA Vol. 93, Developmental Biology; 08/1996; p. 8455-8459 | | | | |
| CSR | Krasikov et al.; α -Glucosidases; Biochemistry (Moscow) Vol. 66, No. 3; 2001; p. 267-281 | | | | |
| CTR | Kruger et al.; 90-Day Oral Toxicity Study of D-Tagatose in Rats; Regulatory Toxicology and Pharmacology 29; 1999; p. S1-S10 | | | | |
| CUR | Kwon et al.; <i>Cyclo</i> (Dehydroal-L-Leu), an α -Glucosidase Inhibitor from <i>Penicillium</i> sp. F70614; The Journal of Antibiotics Vol. 53, No. 9; 09/2000; p. 954-958 | | | | |
| CVR | Laloux et al.; On the mechanism by which glucocorticoids cause the activation of glycogen synthase in mouse and rat livers; Eur. J. Biochem. 136; 1983; p. 175-181 | | | | |
| CWR | Lam et al.; A new type of synthetic peptide library for identifying ligand-binding activity; Nature Vol. 354; 11/1991; p. 82-84 | | | | |
| CXR | Latsis et al.; Diverse effects of two allosteric inhibitors on the phosphorylation state of glycogen phosphorylase in hepatocytes; Biochem. J. 368; 2002; p. 309-316 | | | | |
| CYR | Leclerc et al.; Indirubins Inhibit Glycogen Synthase Kinase-3 β and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease; The Journal of Biological Chemistry Vol. 276, No. 1; 01/2001; p. 251-260 | | | | |
| CZR | Legler et al.; <i>N</i> ¹ -Alkyl-D-gluconamides: Are they 'perfect' mimics of the first transition state of glucosidase action?; Carbohydrate Research 292; 1996; p. 103-115 | ✓ | | | |

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

| | | |
|-------------------|----------------|-------------|
| Atty. Dkt. No. | M# | Client Ref. |
| | 029996-0306374 | |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| |
|--|
| Applicant: Pownall, et al. |
| Appln. No.: 10/697,700 |
| Filing Date: October 29, 2003 |
| Examiner: to be assigned Art Unit: to be assigned |

Date: February 13, 2004 Page **9** of **13**

| OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) | | | English Abstract | | Translation Readily Available | |
|---|-----|---|---------------------|----|-------------------------------------|----|
| Examiner's Initials* | | | Enclosed | No | Enclosed | No |
| | DAR | Lembcke et al.; Lysosomal storage of glycogen as a sequel of α -glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248); Research in Experimental Medicine 191; 1991; p. 389-404 | / | | | |
| | DBR | Lingohr et al.; Dichloroacetate Stimulates Glycogen Accumulation in Primary Hepatocytes through an Insulin-Independent Mechanism; Toxicological Sciences 68; 2002; p. 508-515 | | | | |
| | DCR | Lochhead et al.; Inhibition of GSK-3 Selectively Reduces Glucose-6-Phosphatase and Phosphoenolpyruvate Carboxykinase Gene Expression; Diabetes 50; 2001; p. 937-946 | | | | |
| | DDR | Lindgren et al.; NN 42-1007 is a novel, potent inhibitor of hepatic glycogen phosphorylase, and of hepatocyte glycogenolysis; Diabetes Abstract Book 56 th Annual Meeting and Scientific Sessions; 05/1996; p. 142A:521 | | | | |
| | DER | Martinez et al.; Glycogen Synthase Kinase 3 (GSK-3) Inhibitors as New Promising Drugs for Diabetes, Neurodegeneration, Cancer, and Inflammation; Medicinal Research Reviews, Vol. 22, No. 4; 2002; p. 373-384 | | | | |
| | DFR | Martinez et al.; First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3 β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease; Journal of Medical Chemistry Vol. 45, No. 6; 2002; p. 1292-1299 | | | | |
| | DGR | Massillon et al.; Demonstration of a Glycogen/Glucose 1-Phosphate Cycle in Hepatocytes from Fasted Rats; The Journal of Biological Chemistry Vol. 270, No. 33; 08/1995; p. 19351-19356 | | | | |
| | DHR | Matsumoto et al.; A Novel Method for the Assay of α -Glucosidase Inhibitory Activity Using a Multi-channel Oxygen Sensor; Analytica Sciences Vol. 18; 12/2002; p. 1315-1319 | | | | |
| | DIR | Matsuura et al.; α -Glucosidase Inhibitor from the Seeds of Balsam Pear (Momordica charantia) and the Fruit Bodies of <i>Grifola frondosa</i> ; Biosci. Biotechnol. Biochem. 66 (7); 2002; p. 1576-1578 | | | | |
| | DJR | Meijer et al.; Inhibition of cyclin-dependent kinases, GSK-3 β and CK1 by hymenialdisine, a marine sponge constituent; Chemistry & Biology Vol. 7, No. 1; 2000; p. 51-63 | | | | |

| | |
|----------|------------------|
| Examiner | Date Considered: |
|----------|------------------|

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

029996-0306374

Applicant: Pownall, et al.

Appln. No.: 10/697,700

Filing Date: October 29, 2003

Examiner: to be assigned

Art Unit: to be assigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: February 13, 2004

Page

10

of

13

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner's

Initials*

English

Abstract

Translation

Readily
Available

Enclosed

No

Enclosed


No

| | | | | | |
|-----|---|--|--|--|--|
| DKR | Mettey et al.; Aloisines, a New Family of CDK/GSK-3 Inhibitors, ASR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects; Journal of Medical Chemistry Vol. 46, No. 2; 2003; p. 222-236 | | | | |
| DLR | Mitchell et al.; Ternary Complex Crystal Structure of Glycogen Phosphorylase with the Transition State Analogue Nojirimycin Tetrazole and Phosphate in the T and R States; Biochemistry Vol. 35, No. 23; 1996; p. 7341-7355 | | | | |
| DMR | Molyneux et al.; 6-Epicastanospermine, a Novel Indolizidine Alkaloid That Inhibits α -Glucosidase; Archives of Biochemistry and Biophysics Vol. 251; No. 2; 12/1986; p. 450-457 | | | | |
| DNR | Muraoka et al.; Synthesis of a Nitrogen Analogue of Salacinol and Its α -Glucosidase Inhibitory Activity; Chem. Pharm. Bull. Vol. 49, No. 11; 11/2001; p. 1503-1505 | | | | |
| DOR | Nakai et al.; Adeno-Associated Viral Vector-Mediated Gene Transfer of Human Blood Coagulation Factor IX Into Mouse Liver; Blood, Vol. 91, No. 12; 06/1998; p. 4600-4607 | | | | |
| DPR | Nakao et al.; Callyspongynic Acid, a Polyacetylenic Acid Which Inhibits α -Glucosidase, from the Marine Sponge <i>Callyspongia truncata</i> ; Journal of Natural Products Vol. 65, No. 6; 2002; p. 922-924 | | | | |
| DQR | Oikonomakos et al.; The design of potential antidiabetic drugs: experimental investigation of a number of β -D-glucose analogue inhibitors of glycogen phosphorylase; European Journal of Drug Metabolism and Pharmacokinetics, No. 3; 1994; p. 185-192 | | | | |
| DRR | Oikonomakos et al.; Binding of <i>N</i> -acetyl- <i>N'</i> - β -D-glucopyranosyl urea and <i>N</i> -benzoyl- <i>N'</i> - β -D-glucopyranosyl urea to glycogen phosphorylase <i>b</i> ; Eur. J. Biochem. 269; 2002; p. 1684-1696 | | | | |
| DSR | Oikonomakos et al.; Flavopiridol Inhibits Glycogen Phosphorylase by Binding at the Inhibitor Site; The Journal of Biological Chemistry Vol. 275, No. 44; 11/2000; p. 34566-34573 | | | | |
| DTR | Oikonomakos et al.; Kinetic and Crystallographic Studies of Glucopyranosylidene Spirothiohydantoin Binding to Glycogen Phosphorylase B; Bioorganic & Medicinal Chemistry 10; 2002; p. 261-268 | | | | |

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

| | | |
|-------------------|----------------|-------------|
| Atty. Dkt. No. | M# | Client Ref. |
| | 029996-0306374 | |


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| |
|--|
| Applicant: Pownall, et al. |
| Appln. No.: 10/697,700 |
| Filing Date: October 29, 2003 |
| Examiner: to be assigned Art Unit: to be assigned |

Date: February 13, 2004 Page 11 of 13

| OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) | | | English Abstract | | Translation Readily Available | |
|---|-----|---|---------------------|----|-------------------------------------|----|
| Examiner's Initials* | | | Enclosed | No | Enclosed | No |
| | DUR | Oikonomakos et al.; Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate; Protein Science 8; 1999; p. 1930-1945 | | | | |
| | DVR | Okazaki et al.; A repeated 28-day oral dose toxicity study of genistein in rats, based on the 'Enhanced OECD Test Guideline 407' for screening endocrine-disrupting chemicals; Arch Toxicol 76; 2002; p. 553-559 | | | | |
| | DWR | Papandréou et al.; The α-Glucosidase Inhibitor 1-Deoxynojirimycin Blocks Human Immunodeficiency Virus Envelope Glycoprotein-Mediated Membrane Fusion at the CXCR4 Binding Step; Molecular Pharmacology, Vol. 61, No. 1; 2002; p. 186-193 | | | | |
| | DXR | Pinotsis et al.; The binding of β- and γ-cyclodextrins to glycogen phosphorylase b: Kinetic and crystallographic studies; Protein Science Vol. 12; 2003; p. 1914-1924 | | | | |
| | DYR | Rhinehart et al.; Quantitative Relationship of Lysosomal Glycogen Accumulation to Lysosomal α-Glucosidase Inhibition in Castanospermine-Treated Rats; Biochemical Pharmacology, Vol. 41, No. 2; 1991; p. 223-228 | | | | |
| | DZR | Rusbridge et al.; 3,4-Dichloroisocoumarin, a serine protease inhibitor, inactivates glycogen phosphorylase b; FEBS Letters Vol. 268, No. 1; 07/1990; p. 133-136 | | | | |
| | EAR | Saunier et al; Inhibition of N-linked Complex Oligosaccharide Formation by 1-Deoxynojirimycin, an inhibitor of Processing Gucosidases; The journal of Biological Chemistry Vol. 257, No. 23; 12/1982; p. 14155-14161 | | | | |
| | EBR | Rathi et al.; The Effect of <i>Momordica charantia</i> and <i>Mucuna pruriens</i> in Experimental Diabetes and their Effect on Key Metabolic Enzymes Involved in Carbohydrate Metabolism; Phytotherapy Research 16; 2002; p. 236-243 | | | | |
| | ECR | Ring et al.; Selective Glycogen Synthase Kinase 3 Inhibitors Potentiate Insulin Activation of Glucose Transport and Utilization in Vitro and in Vivo; Diabetes, Vol. 52; 03/2003; p. 588-595 | | | | |
| | EDR | Roden et al.; Application of NMR Spectroscopy to Study Muscle Glycogen Metabolism in Man; Annu. Rev. Med. 50; 1999; p. 277-290 | | | | |
| | EER | Rousset et al.; Presence and Cell Growth-related Variations of Glycogen in Human colorectal Adenocarcinoma Cell Lines in Culture; Cancer Research 39; 02/1979; p. 531-534 | | | | |

| | |
|--|------------------|
| Examiner | Date Considered: |
| <p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p> | |



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

029996-0306374

Applicant: Pownall, et al.

Appln. No.: 10/697,700

Filing Date: October 29, 2003

Examiner: to be assigned

Art Unit: to be assigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: February 13, 2004

Page

12

of

13

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

| Examiner's Initials* | | | English Abstract | | Translation Readily Available | |
|-------------------------|-----|--|---------------------|----|-------------------------------------|----|
| | | | Enclosed | No | Enclosed | No |
| | EFR | Ryves et al.; Glycogen Synthase Kinase-3 Inhibition by Lithium and Beryllium Suggests the Presence of Two Magnesium Binding Sites; Biochemical and Biophysical Research Communications Vol. 290, No. 3; 2002; p. 967-972 | | | | |
| | EGR | Ryves et al.; Lithium Inhibits Glycogen Synthase Kinase-3 by Competition for Magnesium; Biochemical and Biophysical Research Communications Vol. 280, No. 3; 2001; p. 720-725 | | | | |
| | EHR | San Juan Serrano et al.; Caffeine Inhibition of Glycogen Phosphorylase from Mytilus galloprovincialis Mantle Tissue; Int. J. Biochem. Cell Biol., Vol. 27, No. 9; 1995; p. 911-916 | | | | |
| | EIR | Scott et al.; Searching for Peptide Ligands with an Epitope Library; Science, Vol. 249; 07/1990; p. 386-390 | | | | |
| | EJR | Shiota et al.; Inhibition of glycogenolysis enhances gluconeogenic precursor uptake by the liver of conscious dogs; Am. J. Physiol. 273 (Endocrinol. Metab. 36); 1997; p. E868-E879 | | | | |
| | EKR | Smith et al.; 3-Anilono-4-arylmaleimides: Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 (GSK-3); Bioorganic & Medicinal Chemistry Letters 11; 2001; p. 635-639 | | | | |
| | ELR | Sou et al.; α -Glucosidase Inhibitors with a 4,5,6,7-Tetrachlorophthalimide Skeleton Pendanted with a Cycloalkyl or Dicarba-closo-dodecaborane Group; Chem. Pharm. Bull. Vol. 49, No. 6; 06/2001; p. 791-793 | | | | |
| | EMR | Sugita et al.; Inducible nitric oxide synthase plays a role in LPS-induced hyperglycemia and insulin resistance; Am. J. Physiol. Endocrinol. Metab. 282; 2002; p. E386-E394 | | | | |
| | ENR | Takeuchi et al.; Inhibitory Effect of Pseudo-Aminosugars on Oligosaccharide Glucosidases I and II and on Lysosomal α -Glucosidase from Rat Liver; J. Biochem. 108; 1990; p. 42-46 | | | | |
| | EOR | Tsujii et al.; Nectrisine Is a Potent Inhibitor of α -Glucosidases, Demonstrating Activities Similarly at Enzyme and Cellular Levels; Biochemical and Biophysical Research Communications Vol. 220, No. 2; 1996; p. 459-466 | | | | |
| | EPR | ter Haar et al.; Structure of GSK3 β reveals a primed phosphorylation mechanism; Nature Structural Biology, Vol. 8, no. 7; 07/2001; p. 593-596 | | | | |

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

029996-0306374

Applicant: Pownall, et al.

Appln. No.: 10/697,700

Filing Date: October 29, 2003

Examiner: to be assigned

Art Unit: to be assigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: February 13, 2004

Page

13

of

13

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

| Examiner's Initials* | | | English Abstract | | Translation Readily Available | |
|-------------------------|-----|---|---------------------|----|-------------------------------------|----|
| | | | Enclosed | No | Enclosed | No |
| | EQR | Thomas et al.; A GSK3-binding peptide from FRAT1 selectively inhibits the GSK 3-catalysed phosphorylation of Axin and β -catenin; FEBS Letters 458; 1999; p. 247-251 | | | | |
| | ERR | Tropea et al.; Australine, a Pyrrolozidine Alkaloid That Inhibits Amyloglucosidase and Glycoprotein Processing; Biochemistry Vol. 28, No. 5; 1989; p. 2027-2034 | | | | |
| | ESR | Van Schaftingen et al.; Effect of proglycosyn and other phenolic compounds on glycogen metabolism in isolated hepatocytes; Eur. J. Biochem. 218; 1993; p. 745-751 | | | | |
| | ETR | Vivinus et al.; An element within the 5' untranslated region of human <i>Hsp70</i> mRNA which acts as a general enhancer of mRNA translation; Eur. J. Biochem. 268; 2001; p. 1908-1917 | | | | |
| | EUR | Waagepetersen et al.; The effects of isofagomine, a potent glycogen phosphorylase inhibitor, on glycogen metabolism in cultured mouse cortical astrocytes; Neurochemistry International 36; 2000; p. 435-440 | | | | |
| | EVR | Watson et al.; Design of Inhibitors of Glycogen Phosphorylase: A Study of α - and β -C-Glucosides and 1-Thio- β -D-glucose Compounds; Biochemistry Vol. 33, No. 19; 1994; p. 5745-5758 | | | | |
| | EWR | Wang et al.; Cytotoxic effects of cantharidin on the growth of normal and carcinoma cells; Toxicology 147; 2000; p. 77-87 | | | | |
| | EXR | Wigler et al.; Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells; Cell Vol. 11; 05/1977; p. 223-232 | | | | |
| | EYR | Withers; Pyridoxal(5')diphospho(1)- α -D-glucose The Journal of Biological Chemistry, Vol. 260, No. 2; 01/1985; p. 841-845 | | | | |
| | EZR | Yoshikawa et al.; Absolute Stereostructure of Potent α -Glucosidase Inhibitor, Salacinol, with Unique Thiosugar Sulfonium Sulfate Inner Salt Structure from <i>Salacia reticulata</i> ; Bioorganic & Medicinal Chemistry, 10; 2002; p. 1547-1554 | | | | |
| | FAR | Yan et al.; The Human Acid α -Glucosidase Gene Is a Novel Target of the Notch-1/Hes-1 Signaling Pathway; The Journal of Biological Chemistry, Vol. 277, No. 33; 08/2002; p. 29760-29764 | | | | |
| | FBR | Zuckermann et al.; Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted)glycine Peptoid Library; Journal of Medical Chemistry No. 37, No. 17; 1994; p. 2678-2685 | | | | |

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.